Liver or hepatic disease causes one out of 25 deaths worldwide, with nearly two-thirds of liver-related deaths in men and one-thirds in women.
PBC Landscape - Clinical Trials, Revenue Forecasts
Half The Pipeline From APAC Firms
Primary biliary cholangitis or cirrhosis, PBC, is a lesser-known cousin of MASH but a silent killer, nevertheless. Scrip studies data from Citeline’s Pharmaprojects and separately Evaluate Pharma to reveal a promising pipeline and drug revenue forecasts, with APAC firms accounting for half the pipeline of drugs
More from Clinical Trials
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
More from Rare Diseases
• By
The founder and CEO of Ultragenyx talked with Scrip as the company approaches a pivotal data readout and awaits US FDA action on its first gene therapy.
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
• By
Amvuttra will target a substantially larger patient population with a new indication, but it is third to market behind Pfizer’s Vyndaqel and Bridge Bio’s Attruby and will cost more.